학술논문
성문상부암의 치료결과
이용수 10
- 영문명
- Treatment Results for Supeaglottic Cancer
- 발행기관
- 대한방사선종양학회
- 저자명
- 이규찬(Kyuchang Lee) 김철용(Chul Yong Kim) 최명선(Myung Sun Choi)
- 간행물 정보
- 『대한방사선종양학회지』제12권 제3호, 323~329쪽, 전체 7쪽
- 주제분류
- 의약학 > 종양학
- 파일형태
- 발행일자
- 1994.11.30
4,000원
구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.
국문 초록
영문 초록
Purpose : In supraglottic cancer, radiation therapy is used to preserve the laryngeal function but combined surgery and radiation therapy is required in advanced stage. The authors present the results of radiation therapy alone and combined surgery plus postoperative radiation therapy for supraglottic cancer.
Methods and Materials : A retrospective analysis was done for 43 patients with squamous cell carcinoma of the supraglottic larynx who were treated from Feburary 1982 to December 1991, in the Department of Radiation Oncology. Korea Universiry Hospital. Patient distribution according to the AJCC staging system was as foolows; Ⅰ, 3(7.0%); Ⅱ, 7(16.3%); Ⅲ, 17(39.5%); Ⅳ, 16(37.2%). Patients age ranged from 30 to 72 year (median 62). Follow up durations were from 21 to 137 months(median 27). Seventeen patients(39.5%) were treated by radiation therapy alone with radiation dose of 6840 7380 cGy and 26 patients(60.5%) were treated with surgery plus postoperative irradiation with doses of 5820-6660 cGy.
Results : Overall five-year survival rate for all stage was 51.8%, with 100% for Stage Ⅰ and Ⅱ, 47.3% for Stage Ⅲ and 29.2% for Stage Ⅳ. The difference of the survival rate by stage was statistically significant(p=0.0152). Five-year survival rate were 100% for locally confined tumor in the supraglottic larynx, 37.5% for transglottic extension, 26.7% for hypopharynx extension, and only two of 5 patients with both transglottic and hypopharynx extension were alive(p=0.0033), Five-year survival rate by neck node status were as follows; 55.0% for NO. 64.3$ for N1, 50.0% for N2, and all 2 of N3 were died of disease. Overall survival rate for radiation therapy alone group was 42.8% and it was 56.7% for surgery plus postoperative radiation therapy group with no statistically significant difference(p=0.5215). In Stage Ⅰ and Ⅱ, all patients survived. In Stage Ⅲ and Ⅳ, 5-year survival rate for radiation therapy alone group was 28.5% and 43.4% for surgery plus postoperative irradiation group(p=0.5103). Local control rate was 58.8%(10/17) for radiation therapy alone group and 73.1%(19/26) for surgery plus postoperative irradiation group. Three patients form surgery plus postoperative radiation therapy group developed distant metastasis in lungs.
Conclusion : Treatment results of radiation therapy alone was excellent in early stage supraglottic cancer. In advanced stage even the difference was statistically not significant the result of postoperative radiation therapy group was superior compared with radiation therapy alone group. Since 1992, concomitant chemoradiotherapy with hyperfractionated radiotherapy is being used to improve the result of the treatment and preserve the laryngeal function in advanced stage supraglottic cancer.
목차
해당간행물 수록 논문
- 영지버섯의 항암효과
- 자궁경부암의 수술 후 방사선치료 결과
- 성문상부암의 치료결과
- 상악동암의 방사선 치료
- The Radiation Therapy for Spinal Cord Compression in Hematologic Malignancy
- Postoperative Radiation Therapy in Ameloblastoma of the Jaw
- T1-T2 성문암의 방사선 치료 성적
- 방사선조사와 cis-dichorodiammineplatinum(Ⅱ)가 흰쥐의 심근에 미치는 효과에 관한 실험적 연구
- 열소자 온열요법시 VX-2 Hepatoma내의 온도 변화에 대한 연구
- 국소적 위장관 악성 림프종의 치료성적 및 예후인자 분석
- Radiation Therapy of Testicular Seminoma
- 방사선 조사 후 백서 공장 점막의 재생과정에서 5-fluorouracil 투여가 phospholipase C 와 ras 암유전자단백의 발현에 미치는 영향
- Conservative Surgery and Primary Radiotherapy for Early Breast Cancer
참고문헌
관련논문
의약학 > 종양학분야 BEST
- 방사선 치료에 내성이 유도된 두경부 편평세포암에 대한 종양살상 헤르페스 바이러스의 유전자 치료 효과
- 식도암에서 근치적 절제술 후 방사선치료의 역할
- 두경부암에서 면역회피 기전과 면역항암제 치료
의약학 > 종양학분야 NEW
- Radiomics in stereotactic body radiotherapy for non-small cell lung cancer: a systematic review and radiomic quality score study
- Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 1. Brain and head and neck
- Hypofractionated radiation therapy for head and neck cancers in the era of intensity-modulated radiation therapy
최근 이용한 논문
교보eBook 첫 방문을 환영 합니다!
신규가입 혜택 지급이 완료 되었습니다.
바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!